Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Circulation

• Publication date

  2001-05-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.103.21.2572PMID 11382726
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961

  2000cited by this paper
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.

  2000cited by this paper
• Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.

  1999cited by this paper
• Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.

  1999cited by this paper
• Rapid platelet-function assay: an automated and quantitative cartridge-based method.

  1999cited by this paper
• Efficacy of Abciximab Induced Platelet Blockade Using a Rapid Point of Care Assay

  1999cited by this paper
• Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.

  1998cited by this paper
• Long‐Term Protection from Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade with Percutaneous Coronary Intervention

  1998cited by this paper
• Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.

  1997cited by this paper
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

  1997cited by this paper
• Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.

  1997cited by this paper
• Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.

  1997cited by this paper
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention : IMPACT-II

  1997cited by this paper
• Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention

  1997cited by this paper
• Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.

  1996cited by this paper
• Adhesion Receptors as Therapeutic Targets

  1995cited by this paper
• Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention.

  1995cited by this paper
• Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.

  1995cited by this paper
• Randomized Trial of a GPIIb/IIIa Platelet Receptor Blocker in Refractory Unstable Angina

  1994cited by this paper
• Pharmacokinetics and pharmacodynamics of MK‐383, a selective non‐peptide platelet glycoprotein‐IIb/IIIa receptor antagonist, in healthy men

  1994cited by this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cited by this paper
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

  1994cited by this paper
• Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors.

  1989cited by this paper
• Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.

  1988cited by this paper
• A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.

  1983cited by this paper

• Safety and efficacy of tirofiban in the endovascular treatment of intracranial aneurysms: a systematic evaluation and meta-analysis

  2025cites this paper
• A Multi-Center Evaluation of Clopidogrel Resistance and its Role in Predicting Stent Thrombosis in Transcarotid Artery Revascularization.

  2024cites this paper
• Increased Platelet Adhesiveness in Patients with Venous Thromboembolic Disease

  2024cites this paper
• Effect of cocoa (Theobroma cacao L.) on platelet function testing profiles in patients with coronary artery disease: ECLAIR pilot study

  2022cites this paper
• Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens

  2022cites this paper
• The safety and efficacy of a low dose of tirofiban for early complications during and after stent-assisted coiling of ruptured intracranial aneurysms: A propensity matching study.

  2022cites this paper
• Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline.

  2022cites this paper
• Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome

  2021influential citation
• Acute Stenting and Concomitant Tirofiban Administration for the Endovascular Treatment of Acute Ischemic Stroke Related to Intracranial Artery Dissections: A Single Center Experience and Systematic Review of the Literature.

  2021cites this paper
• CLINICAL RESEARCH

  2021cites this paper
• Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist

  2021cites this paper
• The Prophylactic Use of Tirofiban versus Oral Antiplatelet Medications in Stent-Assisted Coiling of Intracranial Aneurysms: A Meta-analysis

  2021cites this paper
• Increased risk of Ventriculostomy-Associated hemorrhage in patients treated with antiplatelet agents for stent-assisted coiling of ruptured intracranial aneurysms

  2020cites this paper
• Prophylactic administration of tirofiban for preventing thromboembolic events in flow diversion treatment of intracranial aneurysms

  2020cites this paper
• Acute coronary syndromes with high thrombotic burden: therapeutic innovations

  2020cites this paper
• Impact of renin angiotensin system inhibitors on homocysteine levels and platelets reactivity in patients on dual antiplatelet therapy.

  2020cites this paper
• Antiplatelet Drugs for Neurointerventions: Part 1 Clinical Pharmacology

  2020cites this paper
• First Human Use of RUC‐4: A Nonactivating Second‐Generation Small‐Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point‐of‐Care Treatment of ST‐Segment–Elevation Myocardial Infarction

  2020cites this paper
• Laboratory Monitoring of Antiplatelet Therapy

  2019cites this paper
• Clinical Tests of Platelet Function

  2019cites this paper
• Homocysteine levels and platelet reactivity in coronary artery disease patients treated with ticagrelor.

  2019cites this paper
• Preliminary Study of Tirofiban Infusion in Coil Embolization of Ruptured Intracranial Aneurysms

  2018cites this paper
• Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?

  2018cites this paper
• Treatment of Acute Ischemic Stroke

  2018cites this paper
• Monitoring of Antiplatelet Therapy

  2017cites this paper
• Die Bedeutung der point-of-care-Genotypisierung in der antithrombozytären Therapie mit neuen P2Y12-Antagonisten bei Akutem Koronarsyndrom

  2017cites this paper
• Intracoronary high-dose bolus tirofiban administration during complex coronary interventions: A United States-based case series.

  2017cites this paper
• Intravenous administration of tirofiban versus loading dose of oral clopidogrel for preventing thromboembolism in stent-assisted coiling of intracranial aneurysms

  2017cites this paper
• Ticagrelor and Epti fi batide Bolus Versus Ticagrelor and Epti fi batide Bolus With 2-Hour Infusion in High-Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

  2017cites this paper
• Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention

  2017cites this paper
• CLINICAL OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH ACS TREATED WITH CONCOMITANT USE OF TICAGRELOR AND CLOPIDOGREL.

  2017cites this paper
• Markers of Platelet Function

  2016cites this paper
• Eptifibatide infusion versus placebo in high risk patients with non-ST segment elevation acute coronary syndromes managed with urgent coronary artery bypass graft surgery. A prospective multicenter randomized placebo-controlled clinical trial.

  2016cites this paper
• A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.

  2016cites this paper
• The Role of Platelet Function Testing in the Development of Platelet Inhibitors

  2016cites this paper
• Current Role of Platelet Glycoprotein IIb/IIIa Inhibition in the Therapeutic Management of Acute Coronary Syndromes in the Stent Era

  2016cites this paper
• chieved Platelet Aggregation Inhibition fter Different Antiplatelet Regimens uring Percutaneous Coronary Intervention or ST-Segment Elevation Myocardial Infarction

  2016influential citation
• ptimal Antiplatelet herapy During Percutaneous oronary Interventions Includes lycoprotein IIb / IIIa Inhibitors ust Eliminate the Infusion *

  2016cites this paper
• Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban

  2016cites this paper
• General Aspects of Platelet Function Tests

  2016cites this paper
• INCIDENCE OF ANTIPLATELET DRUG RESISTANCE AND TRIPLE ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROME

  2016cites this paper
• Homocysteine Levels Influence Platelet Reactivity in Coronary Artery Disease Patients Treated With Acetylsalicylic Acid

  2015cites this paper
• Relation of Level of Platelet Inhibition after Eptifibatide with Major Cardiovascular Events in ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

  2015cites this paper
• Dual antiplatelet therapy after coronary artery bypass grafting: Do we have a consensus?

  2015cites this paper
• Effect of Intracoronary Plus Low-Dose Intravenous Tirofiban in Elderly Patients with Acute Myocardial Infarction.

  2015cites this paper
• Clinical Presentation, Imaging, and Management of Complications due to Neurointerventional Procedures

  2015cites this paper
• Safety and efficacy of a new prophylactic tirofiban protocol without oral intraoperative antiplatelet therapy for endovascular treatment of ruptured intracranial aneurysms

  2015cites this paper
• Impedanzaggregometrische Analyse der Plättchenfunktion von Apherese-Thrombozytenkonzentraten in Abhängigkeit von der Lagerungsdauer

  2014cites this paper
• Antiplatelet response to aspirin and clopidogrel in patients with coronary artery disease undergoing percutaneous coronary intervention

  2014cites this paper
• Treatment of Acute Ischaemic Stroke

  2013cites this paper
• Current Concepts in the Clinical Utility of Platelet Reactivity Testing.

  2013cites this paper
• Intracranial Aneurysm Treatment

  2013cites this paper
• receptor density and the response to SFLLRN An intronic polymorphism in the PAR-1 gene is associated with platelet

  2013cites this paper
• Platelet biology: the role of shear

  2013cites this paper
• Platelet biology: the role of shear.

  2013cites this paper
• Monitoring and Reversal of Anticoagulation and Antiplatelets.

  2013cites this paper
• Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI.

  2013cites this paper
• Diagnostic Assessment of Platelet Function

  2013cites this paper
• Assessment of Platelet Inhibition by Point-of-Care Testing in Neuroendovascular Procedures

  2013cites this paper
• General Considerations for Neurointerventional Procedures

  2013cites this paper
• Plateletworks®

  2012cites this paper
• Clinical Practice Guidelines Evidence-Based College of Chest Physicians Prevention of Thrombosis, 9th ed: American Therapy : Antithrombotic Therapy and Perioperative Management of Antithrombotic

  2012cites this paper
• Obesity and intracranial in-stent thrombosis

  2012cites this paper
• Thienopyridines and other ADP-receptor antagonists.

  2012cites this paper
• Combination of Low Molecular Weight Heparins with Antiplatelet Agents in Non-ST Elevation Acute Coronary Syndromes

  2012cites this paper
• Contemporary use of glycoprotein IIb/IIIa inhibitors

  2012cites this paper
• An Automated Lab-on-a-CD System for Parallel Whole Blood Analyses

  2012cites this paper
• Balloon-Expandable Stent Placement in Patients with Immediate Reocclusion after Initial Successful Thrombolysis of Acute Middle Cerebral Arterial Obstruction

  2012cites this paper
• Effect of antithrombotic drugs on platelet function and receptors and an investigation into platelet cholesterol

  2012cites this paper
• Glycoprotein IIb/IIIa Antagonists in Acute Ischaemic Stroke

  2012cites this paper
• 51. Point-Of-Care Testing in Hemostasis

  2012cites this paper
• Efficacy and Safety of Unfractionated Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Revascularization for an Acute Coronary Syndrome: A Meta‐Analysis of Randomized Trials Performed With Stents and Thienopyridines

  2012cites this paper
• Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR)

  2012cites this paper
• Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Non-ST Segment Elevation Acute Coronary Syndromes

  2012cites this paper
• Platelet Function Profile Post-Clopidogrel Therapy in Patients With Type 2 Diabetes Undergoing Coronary Stent Implantation

  2012cites this paper
• POCT in der Gerinnungsdiagnostik

  2012cites this paper
• Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cites this paper
• Intracoronary bolus‐only compared with intravenous bolus plus infusion of tirofiban application in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention

  2012cites this paper
• Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients wit

  2012cites this paper
• Glycoprotein IIb/IIIa antagonists.

  2012cites this paper
• High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials

  2012cites this paper
• Personalizing Antiplatelet Therapy With Clopidogrel

  2012cites this paper
• Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities

  2012cites this paper
• Effect of tailored antiplatelet therapy on periprocedural myonecrosis in patients with diabetes mellitus (from the DM-Verify Now Trial).

  2012cites this paper
• The role of molecular mimicry in the etiology of Guillain Barré Syndrome

  2011cites this paper
• Association between CYP2C19*2 variant and clinical outcome in Clopidogrel treated patients from Republic of Macedonia

  2011cites this paper
• GPIIb/IIIa inhibitors and aspirin Desmopressin antagonizes the in vitro platelet dysfunction induced by

  2011cites this paper
• Propiedades de los diferentes inhibidores de la glucoproteína IIb/IIIa: ¿se puede aceptar el efecto de clase?

  2011cites this paper
• Comparison of a Point-of-Care Platelet Function Testing to Light Transmission Aggregometry in Patients Undergoing Percutaneous Coronary Intervention Pretreated With Aspirin and Clopidogrel

  2011cites this paper
• Clopidogrel Response Variability and Its Correlation with Early Recurrent Cardiovascular Events in Chinese Patients Undergoing Percutaneous Coronary Intervention

  2011cites this paper
• Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis

  2011cites this paper
• Monitoring in Anesthesia and Perioperative Care: The history of anesthesia and perioperative monitoring

  2011cites this paper
• Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.

  2011cites this paper
• On the use of abciximab in percutaneous coronary intervention.

  2011cites this paper
• Role of platelet function testing in clinical practice: current concepts and future perspectives.

  2011cites this paper
• High platelet reactivity and clinical outcome – Fact and fiction

  2011cites this paper
• Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome: An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial

  2011cites this paper
• In-vitro assessment of platelet function.

  2011cites this paper
• Optimal Use of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Patients Undergoing Percutaneous Coronary Interventions

  2011cites this paper
• Platelet Biology and Implications for Antiplatelet Therapy in Atherothrombotic Disease

  2011cites this paper